Activation of AMPK by simvastatin inhibited breast tumor angiogenesis via impeding HIF-1α-induced pro-angiogenic factor

Abstract

Substantial data from preclinical studies have revealed the biphasic effects of statins on cardiovascular angiogenesis. Although some have reported the anti-angiogenic potential of statins in malignant tumors, however, the underlying mechanism remains poorly understood. The aim of this study is to elucidate the mechanism by which simvastatin, a member of the statin family, inhibits tumor angiogenesis. Simvastatin significantly suppressed tumor cells-conditioned medium (TCM)-induced angiogenic promotion in vitro, and resulted in a dose-dependent anti-angiogenesis in vivo. Further genetic silencing of HIF-1α reduced VEGF and FGF-2 expressions in 4T1 cells and correspondingly ameliorated HUVECs proliferation facilitated by TCM. Additionally, simvastatin induced angiogenic inhibition via a mechanism of post-transcriptional down-regulation of HIF-1α by increasing phosphorylation level of AMP kinase (AMPK). These results were further validated by the fact that AICAR reduced HIF-1α protein level and ameliorated the angiogenic ability of endothelial cells in vitro and in vivo. Critically, inhibition of AMPK phosphorylation by compound C almost completely abrogated simvastatin-induced anti-angiogenesis, which was accompanied by the reduction of protein levels of HIF-1α and its downstream pro-angiogenic factors. These findings demonstrate the mechanism in which simvastatin induces tumor anti-angiogenesis, and therefore identify the target that explains the beneficial effects of statins on malignant tumors.

This article is protected by copyright. All rights reserved.

from Cancer via ola Kala on Inoreader http://ift.tt/2FJKoh7
via IFTTT